| Literature DB >> 29033550 |
Karin Bæk Knudsen1, Tacjana Pressler2, Laust Hvas Mortensen3, Mary Jarden3,4, Kirsten Arntz Boisen5, Marianne Skov2, Alexandra L Quittner6, Terese Lea Katzenstein1,7.
Abstract
BACKGROUND: Over the last two decades, lifespan has increased significantly for people living with cystic fibrosis (CF). However, several studies have demonstrated that many young adults with CF report mental health problems and poor adherence to their prescribed treatments, challenging their long-term physical health. Treatment guidelines recommend interventions to improve adherence and self-management. The aim of this study was to test the feasibility of a life coaching intervention for young adults with CF.Entities:
Keywords: adherence; chronic disease; depression; life coaching; quality of life
Year: 2017 PMID: 29033550 PMCID: PMC5614776 DOI: 10.2147/PPA.S141267
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Figure 1Participant flow chart.
Baseline demographics and clinical characteristics
| Total | Intervention group | Control group | ||
|---|---|---|---|---|
| Number | 38 | 18 | 20 | |
| Age, mean (range) | 23.7 (18–30) | 23.6 (18–30) | 23.7 (18–29) | NS |
| Females, n (%) | 27 (71) | 12 (67) | 15 (75) | NS |
| BMI (kg/m2), mean (SD) | 22.1 (3.8) | 21.7 (3.9) | 22.5 (3.9) | NS |
| FEV1 % predicted, mean (SD) | 73.4 (23) | 71.3 (24.7) | 75.5 (21.9) | NS |
| FEV1 (≤40%), n (%) | 5 (13) | 3 (17) | 2 (10) | |
| FEV1 (41%–70%), n (%) | 14 (37) | 7 (39) | 7 (35) | |
| FEV1 (>71%), n (%) | 19 (50) | 8 (44) | 11 (55) | |
| HbA1C%, mean (SD) | 6.15 (1.50) | 6.42 (1.69) | 5.86 (1.23) | NS |
| CFTR mutation classes 1 or 2 | 36 (95) | 18 (100) | 18 (90) | NS |
| Chronic pulmonary infection, | 21 (55) | 10 (56) | 11 (55) | NS |
| CFRD, n (%) | 12 (32) | 8 (44) | 4 (20) | NS |
| Single, | 19 (58) | 10 (56) | 9 (45) | NS |
| Lower education, n (%) | 11 (29) | 5 (28) | 6 (30) | NS |
| High school, n (%) | 12 (32) | 5 (28) | 7 (35) | NS |
| College/university, n (%) | 15 (39) | 8 (45) | 7 (35) | NS |
| Employed or studying, n (%) | 33 (87) | 15 (83) | 18 (90) | NS |
| Incapacitated to work/study, n (%) | 3 (8) | 2 (11) | 1 (5) | NS |
Notes:
Pseudomonas aeruginosa, Achromobacter xylosoxidans, and Burkholderia species.
Single status is self-reported and defined as not having a romantic partner.
Abbreviations: FEV1, forced expiratory volume in 1 second; HbA1C, glycated hemoglobin; CFTR, cystic fibrosis transmembrane regulator protein; CFRD, cystic fibrosis-related diabetes; NS, nonsignificant; SD, standard deviation; BMI, body mass index.
Means and standard deviations of health-related quality of life scores from the CFQ-R at baseline, midway, post-intervention, and follow-up
| Measured outcome | Treatment | Baseline
| Midway | Post-intervention | Follow-up (1 year | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | ||
| Physical Functioning | Coaching | 75 (31.6) | 18 | 74.4 (35.1) | 13 | 81.9 (23.1) | 9 | 68.2 (36.8) | 12 |
| Control | 80.2 (19.7) | 20 | 76 (26) | 17 | 80.3 (21) | 18 | 78.5 (30.6) | 12 | |
| Role Limitations | Coaching | 82.5 (15.8) | 18 | 80.6 (16.8) | 12 | 78.1 (19.9) | 8 | 81.1 (13.5) | 11 |
| Control | 77.9 (20.3) | 20 | 73.4 (25.3) | 17 | 83.8 (16.0) | 18 | 87.9 (14.6) | 11 | |
| Vitality | Coaching | 46.8 (21.8) | 18 | 51.8 (21) | 13 | 49.1 (16.4) | 9 | 46.5 (22.6) | 12 |
| Control | 48.5 (18.9) | 20 | 50.8 (16.0) | 17 | 63.9 (18.5) | 18 | 57.2 (21.2) | 12 | |
| Emotional Functioning | Coaching | 67.7 (19.2) | 18 | 69.5 (20.7) | 13 | 68.1 (17.2) | 9 | 67.8 (21.6) | 12 |
| Control | 71 (21.2) | 20 | 72.5 (17.1) | 17 | 76.9 (11.3) | 18 | 76.7 (19.2) | 12 | |
| Social Functioning | Coaching | 67.9 (22.0) | 18 | 72.2 (20.9) | 13 | 67.9 (28.6) | 9 | 67.1 (22.2) | 12 |
| Control | 70.7 (18.2) | 20 | 70.7 (16.8) | 17 | 75.9 (15.2) | 18 | 70.8 (24.4) | 12 | |
| Body Image | Coaching | 73.5 (25.3) | 18 | 75.4 (18.6) | 13 | 72.8 (26.1) | 9 | 69.4 (25.6) | 12 |
| Control | 76.1 (25.8) | 20 | 84.3 (20.1) | 17 | 79.6 (21) | 18 | 86.1 (15.8) | 12 | |
| Eating Disturbance | Coaching | 89.5 (21.7) | 18 | 88.9 (23.9) | 13 | 90.1 (15.2) | 9 | 93.5 (11.1) | 12 |
| Control | 89.4 (22.9) | 20 | 88.2 (21.7) | 17 | 90.4 (15.2) | 18 | 86.1 (19.0) | 12 | |
| Treatment Burden | Coaching | 52.5 (20.8) | 18 | 52.4 (24.8) | 13 | 51.9 (18.4) | 9 | 51.9 (16.6) | 12 |
| Control | 47.9 (21.9) | 20 | 52.3 (22.5) | 17 | 56.8 (22.2) | 18 | 57.4 (25.4) | 12 | |
| Health Perception | Coaching | 58.6 (25.5) | 18 | 57.9 (29) | 13 | 51.9 (26.1) | 9 | 48.1 (26.1) | 12 |
| Control | 58.3 (24.9) | 20 | 56.9 (20) | 17 | 60.5 (23.9) | 18 | 58.3 (29.3) | 12 | |
| Weight Problems | Coaching | 77.8 (37.9) | 18 | 88.1 (28.1) | 13 | 77.8 (33.3) | 9 | 80.6 (26.4) | 12 |
| Control | 83.3 (36.7) | 20 | 80.4 (35.5) | 17 | 83.3 (30.8) | 18 | 80.6 (38.8) | 12 | |
| Respiratory Symptoms | Coaching | 65.6 (19.6) | 18 | 61.5 (18.7) | 13 | 60.5 (16.5) | 9 | 60.2 (23.9) | 12 |
| Control | 67.2 (25) | 20 | 73.3 (21.6) | 17 | 70.1 (22.6) | 18 | 70.8 (20.3) | 12 | |
| Digestive Symptoms | Coaching | 74.1 (25.2) | 18 | 65.9 (20.7) | 13 | 67.9 (23.9) | 9 | 61.1 (23.5) | 12 |
| Control | 71.1 (27.1) | 20 | 81.3 (15.0) | 16 | 75.7 (18.7) | 16 | 73.7 (25.5) | 11 | |
Abbreviations: SD, standard deviation; CFQ-R, Cystic Fibrosis Questionnaire revised version.
Means and standard deviations of secondary outcomes at baseline, midway, post-intervention, and follow-up
| Measured outcome | Treatment | Baseline
| Midway | Post-intervention | Follow-up (1 year | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | ||
| Dornase alfa | Coaching | 4.25 (2.43) | 16 | 4.45 (2.44) | 13 | 4.67 (2.37) | 9 | 4.70 (1.87) | 11 |
| Control | 3.86 (2.73) | 18 | 3.72 (2.33) | 15 | 3.53 (2.67) | 15 | 2.98 (1.77) | 10 | |
| Pancreatic enzymes | Coaching | 5.11 (2.19) | 18 | 4.88 (1.95) | 12 | 5.53 (1.99) | 9 | 5.23 (2.15) | 12 |
| Control | 6.08 (1.56) | 18 | 5.88 (1.66) | 17 | 6.32 (1.49) | 17 | 5.39 (2.12) | 11 | |
| Vitamins supplement | Coaching | 5.14 (2.56) | 18 | 5.13 (2.19) | 13 | 5.94 (2.06) | 9 | 5.04 (2.30) | 12 |
| Control | 4.93 (2.56) | 20 | 5.24 (2.70) | 17 | 5.69 (2.51) | 18 | 5.69 (2.51) | 11 | |
| Inhaled antibiotics | Coaching | 4.50 (2.45) | 14 | 4.52 (2.45) | 13 | 4.97 (2.47) | 8 | 4.40 (2.46) | 8 |
| Control | 5.04 (2.54) | 18 | 5.03 (2.48) | 16 | 5.30 (2.31) | 15 | 4.39 (2.32) | 11 | |
| PEP | Coaching | 3.81 (2.66) | 16 | 3.92 (2.84) | 13 | 4.17 (2.50) | 9 | 3.79 (2.55) | 12 |
| Control | 3.62 (2.96) | 19 | 3.36 (2.55) | 16 | 3.36 (2.76) | 16 | 2.78 (1.34) | 10 | |
| GSE | Coaching | 32.1 (5.71) | 18 | 33.2 (5.27) | 13 | 32.9 (6.58) | 9 | 30.4 (6.44) | 11 |
| Control | 32.9 (4.12) | 20 | 34.1 (4.63) | 16 | 34.9 (4.39) | 18 | 34.6 (4.32) | 11 | |
| MDI | Coaching | 13.6 (7.82) | 18 | 13.4 (11.2) | 13 | 11.9 (7.03) | 9 | 12.9 (8.67) | 12 |
| Control | 13.3 (10.7) | 20 | 10.9 (6.95) | 17 | 9.18 (6.00) | 17 | 10.9 (9.76) | 12 | |
| CES-D | Coaching | 7.89 (10.8) | 18 | 11.3 (11.4) | 13 | 9.71 (7.11) | 7 | 13.3 (10.3) | 12 |
| Control | 9.10 (9.85) | 20 | 12.5 (8.94) | 16 | 10.1 (8.51) | 18 | 12.8 (10.8) | 12 | |
| FEV1 | Coaching | 71.3 (24.7) | 18 | 74.4 (27.9) | 18 | 69.9 (25.3) | 18 | 71.0 (23.0) | 17 |
| Control | 75.5 (21.9) | 20 | 73.9 (22.5) | 20 | 73.5 (19.2) | 19 | 75.2 (23.2) | 19 | |
| BMI | Coaching | 21.7 (3.91) | 18 | 22.5 (4.59) | 18 | 22.0 (4.23) | 18 | 22.2 (3.78) | 17 |
| Control | 22.5 (3.93) | 20 | 22.7 (4.06) | 20 | 22.1 (3.48) | 19 | 23.2 (4.53) | 19 | |
| HbA1c | Coaching | 6.41 (1.69) | 17 | 5.99 (2.31) | 14 | 6.65 (1.76) | 13 | 6.31 (1.53) | 16 |
| Control | 5.86 (1.24) | 16 | 6.11 (1.13) | 14 | 5.96 (1.31) | 10 | 5.96 (0.87) | 19 | |
Notes:
Scores accessed by MMAS-8. The MMAS (8-item) content, names and trademarks are protected by US copyright and trademark laws. Permission for use of the scale and its coding is required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH,14725 NE 20th St Bellevue, WA 98007, USA; dmorisky@gmail.com.
Abbreviations: SD, standard deviation; MMAS-8, Morisky Medication Adherence Scale-8; PEP, positive expiratory pressure; GSE, General Self-Efficacy; MDI, Major Depres sion Inventory; CES-D, Center for Epidemiologic Studies-Depression Scale; FEV1, forced expiratory volume in 1 second; BMI, body mass index; HbA1c, glycated hemoglobin.
Baseline and post-intervention distribution of adherence and depression scores
| Baseline
| Post-intervention | Follow-up (1 year | |||||
|---|---|---|---|---|---|---|---|
| Total | Coaching | Control | Coaching | Control | Coaching | Control | |
| % | % | % | % | % | % | % | |
| Dornase alfa | 76% | 75% | 78% | 67% | 80% | 72% | 90% |
| Low adherence | |||||||
| Pancreatic enzymes | 50% | 67% | 33% | 67% | 41% | 67% | 55% |
| Low adherence | |||||||
| Vitamine supplements | 58% | 56% | 60% | 56% | 39% | 67% | 64% |
| Low adherence | |||||||
| Inhaled antibiotics | 56% | 64% | 50% | 63% | 53% | 64% | 64% |
| Low adherence | |||||||
| PEP | 74% | 75% | 74% | 78% | 75% | 83% | 100% |
| Low adherence | |||||||
| MDI | 15.7% | 17% | 15% | 22% | 0 | 8.3% | 8.3% |
| Mild depression | |||||||
| MDI | 2.6% | 0 | 5% | 0 | 5.6% | 0 | 17% |
| Moderate depression | |||||||
| MDI | 7.9% | 5.6% | 10% | 0 | 0 | 8.3% | 0 |
| Severe depression | |||||||
| CES-D depression | 26% | 22% | 30% | 22% | 22% | 25% | 25% |
Notes:
Low adherence: Morisky Medication Adherence Scale-8 item scores <6.
Depression: CES-D scores >16.
Abbreviations: PEP, positive expiratory pressure; MDI, Major Depression Inventory; CES-D, Center for Epidemiologic Studies-Depression Scale.
The main effects between the intervention group and the control group over time (baseline, midway, post-intervention, and follow-up) on secondary outcomes
| Measured outcomes | Factor | Partial η2 | Measured outcomes | Factor | Partial η2 | ||
|---|---|---|---|---|---|---|---|
| Physical Functioning | Time | 0.10 | 0.132 | Dornase alpha | Time | 0.17 | 0.137 |
| Group | 0.73 | 0.008 | Group | 0.62 | 0.210 | ||
| Role Limitations | Time | 0.41 | 0.058 | Pancreatic enzymes | Time | 0.20 | 0.103 |
| Group | 0.59 | 0.021 | Group | 0.68 | 0.012 | ||
| Vitality | Time | 0.16 | 0.303 | Vitamins supplement | Time | 0.55 | 0.046 |
| Group | 0.31 | 0.064 | Group | 0.44 | 0.044 | ||
| Emotional Functioning | Time | 0.36 | 0.063 | Inhaled antibiotics | Time | 0.79 | 0.024 |
| Group | 0.52 | 0.027 | Group | 0.95 | 0.001 | ||
| Social Functioning | Time | 0.67 | 0.138 | PEP | Time | 0.08 | 0.186 |
| Group | 0.91 | 0.001 | Group | 0.32 | 0.076 | ||
| Body Image | Time | 0.74 | 0.047 | GSE | Time | 0.31 | 0.094 |
| Group | 0.26 | 0.078 | Group | 0.71 | 0.012 | ||
| Eating Disturbance | Time | 0.43 | 0.049 | MDI | Time | 0.15 | 0.112 |
| Group | 0.61 | 0.017 | Group | 0.35 | 0.059 | ||
| Treatment Burden | Time | 0.62 | 0.034 | CES-D | Time | 0.15 | 0.114 |
| Group | 0.84 | 0.003 | Group | 0.94 | 0.00 | ||
| Health Perception | Time | 0.03 | 0.177 | FEV1 | Time | 0.40 | 0.035 |
| Group | 0.36 | 0.053 | Group | 0.91 | 0.001 | ||
| Weight Problems | Time | 0.73 | 0.020 | BMI | Time | 0.73 | 0.007 |
| Group | 0.91 | 0.001 | Group | 0.62 | 0.012 | ||
| Respiratory Symptoms | Time | 0.18 | 0.096 | HbA1C | Time | 0.17 | 0.226 |
| Group | 0.07 | 0.197 | Group | 0.56 | 0.051 | ||
| Digestive Symptoms | Time | 0.69 | 0.032 | ||||
| Group | 0.68 | 0.013 |
Notes: Data were analyzed using a two-way repeated ANOVA.
Within-subject factors: repeated time measures (baseline, midway, post-intervention, and follow-up).
Between-subject factors: coaching group (n=7)/control group (n=11).
Scores assessed by CFQ-R.
Scores assessed by MMAS-8.
Abbreviations: CFQ-R, Cystic Fibrosis Questionnaire revised version; MMAS-8, Morisky Medication Adherence Scale-8; PEP, positive expiratory pressure; GSE, General Self-Efficacy; MDI, Major Depression Inventory; CES-D, Center for Epidemiologic Studies-Depression Scale; FEV1, forced expiratory volume in 1 second; BMI, body mass index; HbA1c, glycated hemoglobin; ANOVA, analysis of variance.